Vaccinex up as Huntington's disease treatment shows promise
08/08/2022 17:21
** Vaccine developer Vaccinex Inc's VCNX.O shares up
nearly 6% at $1.09
** Co says its experimental drug, pepinemab, slows or
prevents cognitive decline in patients with Huntington's disease
in a mid-stage study, which did not meet primary goal
urn:newsml:reuters.com:*:nGNX1JDBJm
** Adds results highlight potential of drug for impact on
other neurodegenerative and neuroinflammatory diseases including
Alzheimer's
** Huntington's disease is a rare genetic condition that
leads to degeneration of nerve cells in brain that affects
movement and cognitive functions
** Including session gains, stock up ~5% YTD
(Reporting by Khushi Mandowara)
((Khushi.Mandowara@thomsonreuters.com;))
Recent news on Vaccinex
See all newsBrief: Vaccinex Reports Third Quarter 2024 Financial Results And Provides Corporate Update
Brief: Vaccinex Says On Oct 7, Got Letter From The Nasdaq Listing Staff Stating That Co Had Not Regained Compliance With The Equity Standard
Brief: VaccinexExercise Of Warrants For $6.2 Million In Gross Proceeds
Brief: Vaccinex Provides Update On New Findings For Signal-Ad Phase 1B/2 Trial Of Pepinemab In Alzheimer’S Disease
Brief: Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease